Deals in Depth: March 2010
GSK penned a $563 million deal with Cellzome for rights to the latter's epigenetics platform. Leading M&A was Teva's $4.5 billion bid for ratiopharm. Biopharma financing dollars rebounded, with notable private transactions including Archimedes's $100 million venture financing, and a $75 million PIPE that Lexicon did concurrent with a $111 million follow-on. Mindray's $151 million FOPO was responsible for over half of all device dollars.
You may also be interested in...
Boston Scientific has agreed to pay $1.07bn to acquire Lumenis’ surgical laser business from Baring Private Equity Asia. See what Meghan Scanlon, president of Boston Scientific’s urology and pelvic health business, said about it here.
US Remains Conservative On Vaccine Dosing Regimens As CDC’s ACIP Highlights Minimal Comfort With Relying On Unproven Correlates
The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices concerns about making COVID-19 vaccine dose regimen changes based on unproven immune correlates of protection could be a warning sign to sponsors about roadblocks they might face if updating vaccines to address viral variants or conducting pediatric studies relying on such surrogate endpoints.
Agency’s unusual public statement about an investigational product's development status may be aimed at countering bullish comments from the sponsor; FDA cites failure of pivotal trial on the primary and secondary endpoints and ‘modest excess in deaths’ with the cell therapy.